0001225208-23-005593.txt : 20230508 0001225208-23-005593.hdr.sgml : 20230508 20230508215411 ACCESSION NUMBER: 0001225208-23-005593 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230505 FILED AS OF DATE: 20230508 DATE AS OF CHANGE: 20230508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOBO DONALD E JR CENTRAL INDEX KEY: 0001196661 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 23899729 MAIL ADDRESS: STREET 1: C/O EDWARDS LIFESCIENCES STREET 2: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 4 1 doc4.xml X0407 4 2023-05-05 0001099800 Edwards Lifesciences Corp EW 0001196661 BOBO DONALD E JR ONE EDWARDS WAY IRVINE CA 92614 1 CVP,Strategy/Corp Development 0 Common Stock 2023-05-05 4 S 0 5635.0000 88.6250 D 56224.6931 D Common Stock 2023-05-07 4 M 0 4767.0000 0 A 60991.6931 D Common Stock 2023-05-07 4 F 0 2968.0000 88.7400 D 58023.6931 D Common Stock 2023-05-08 4 F 0 1399.0000 88.7400 D 56624.6931 D Common Stock 38444.3700 I 401(k) Common Stock 111605.0000 I By Trust Performance Rights 2023-05-07 4 M 0 4767.0000 0.0000 D 2023-05-07 2027-05-06 Common Stock 4767.0000 1308.0000 D On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Linda J. Park, Attorney-in-Fact 2023-05-08